Outcomes of infants born in 2020 to persons infected with Hepatitis B virus and managed by the CDC Perinatal Hepatitis B Prevention Program through the end of 2021 — 64 US Jurisdictions

Print
Related Pages
◀ Figure 4.1
Appendix ▶

Outcomes of infants born in 2020 to persons infected with Hepatitis B virus and managed by the CDC Perinatal Hepatitis B Prevention Program through the end of 2021 — 64 US Jurisdictions

Outcomes of infants born in 2020 to hepatitis B infected persons and managed by the CDC Perinatal Hepatitis B Prevention Program through the end of 2021 in 64 US Jurisdictions.
Hepatitis B Vaccine Administration Post-Vaccination Serologic Testing
Jurisdiction All Infants Managed* HBIG & Vaccine at Birth Complete Series by 12 Months of Age Complete Series After 12 Months of Age Total With Complete Series Received† HBsAg Positive Immune§
No. No. % No. % No. % No. % No. % No. % No. %
Outcomes of infants born in 2018 to hepatitis B infected persons and managed by the CDC Perinatal Hepatitis B Prevention Program through the end of 2019, 64 U.S. Jurisdictions
All Jurisdictions 7,649 7,267 95% 6,612 86% 158 2% 6,770 89% 4,975 65% 20 0% 4,761 96%
State
Alabama 95 59 62% 47 49% 0 0% 47 49% 20 21% 1 5% 18 90%
Alaska 15 14 93% 13 87% 1 7% 14 93% 13 87% 0 0% 12 92%
Arizona 124 117 94% 95 77% 4 3% 99 80% 58 47% 1 2% 55 95%
Arkansas 57 53 93% 44 77% 5 9% 49 86% 39 68% 1 3% 35 90%
California 1,167 1,140 98% 967 83% 13 1% 980 84% 662 57% 0 0% 629 95%
Colorado 130 129 99% 128 98% 0 0% 128 98% 107 82% 0 0% 104 97%
Connecticut 49 38 78% 45 92% 1 2% 46 94% 18 37% 0 0% 17 94%
Delaware 41 40 98% 12 29% 24 59% 36 88% 36 88% 0 0% 35 97%
Florida 339 286 84% 261 77% 0 0% 261 77% 15 4% 0 0% 0 0%
Georgia 250 244 98% 236 94% 4 2% 240 96% 214 86% 0 0% 207 97%
Hawaii 99 99 100% 94 95% 0 0% 94 95% 79 80% 0 0% 79 100%
Idaho 20 20 100% 16 80% 0 0% 16 80% 12 60% 0 0% 12 100%
Illinois 139 138 99% 123 88% 3 2% 126 91% 91 65% 0 0% 85 93%
Indiana 90 90 100% 90 100% 0 0% 90 100% 82 91% 1 1% 81 99%
Iowa 89 84 94% 84 94% 0 0% 84 94% 57 64% 0 0% 52 91%
Kansas 46 43 93% 45 98% 0 0% 45 98% 34 74% 0 0% 31 91%
Kentucky 74 61 82% 56 76% 6 8% 62 84% 23 31% 0 0% 23 100%
Louisiana 112 79 71% 76 68% 2 2% 78 70% 41 37% 1 2% 40 98%
Maine 9 8 89% 8 89% 0 0% 8 89% 6 67% 1 17% 4 67%
Maryland 245 237 97% 124 51% 34 14% 158 64% 154 63% 0 0% 151 98%
Massachusetts 268 266 99% 252 94% 0 0% 252 94% 225 84% 0 0% 222 99%
Michigan 112 110 98% 108 96% 1 1% 109 97% 99 88% 0 0% 97 98%
Minnesota 344 340 99% 324 94% 7 2% 331 96% 272 79% 0 0% 265 97%
Mississippi 52 51 98% 45 87% 0 0% 45 87% 38 73% 0 0% 38 100%
Missouri 101 95 94% 91 90% 2 2% 93 92% 49 49% 0 0% 49 100%
Montana 5 5 100% 5 100% 0 0% 5 100% 4 80% 0 0% 4 100%
Nebraska 51 42 82% 51 100% 0 0% 51 100% 40 78% 0 0% 38 95%
Nevada 61 56 92% 57 93% 0 0% 57 93% 36 59% 0 0% 35 97%
New Hampshire 8 8 100% 7 88% 0 0% 7 88% 3 38% 0 0% 3 100%
New Jersey 226 186 82% 177 78% 5 2% 182 81% 95 42% 0 0% 71 75%
New Mexico 8 7 88% 8 100% 0 0% 8 100% 5 63% 0 0% 4 80%
New York State 221 215 97% 216 98% 3 1% 219 99% 178 81% 0 0% 172 97%
North Carolina 135 128 95% 130 96% 1 1% 131 97% 95 70% 1 1% 91 96%
North Dakota 35 35 100% 22 63% 5 14% 27 77% 12 34% 0 0% 12 100%
Ohio 208 203 98% 193 93% 4 2% 197 95% 100 48% 0 0% 94 94%
Oklahoma 64 61 95% 60 94% 0 0% 60 94% 57 89% 0 0% 55 96%
Oregon 81 75 93% 79 98% 1 1% 80 99% 70 86% 2 3% 56 80%
Pennsylvania 151 146 97% 135 89% 6 4% 141 93% 114 75% 0 0% 110 96%
Rhode Island 26 26 100% 26 100% 0 0% 26 100% 26 100% 0 0% 26 100%
South Carolina 58 52 90% 53 91% 0 0% 53 91% 29 50% 0 0% 25 86%
South Dakota 13 12 92% 12 92% 0 0% 12 92% 10 77% 0 0% 9 90%
Tennessee 89 85 96% 80 90% 0 0% 80 90% 47 53% 1 2% 44 94%
Texas 400 384 96% 312 78% 3 1% 315 79% 235 59% 0 0% 233 99%
Utah 54 51 94% 53 98% 0 0% 53 98% 40 74% 0 0% 37 93%
Vermont 8 5 63% 8 100% 0 0% 8 100% 0 0% 0 0% 0 0%
Virginia 199 189 95% 186 93% 0 0% 186 93% 124 62% 2 2% 122 98%
Washington 195 193 99% 185 95% 1 1% 186 95% 150 77% 1 1% 147 98%
West Virginia 15 14 93% 14 93% 0 0% 14 93% 14 93% 0 0% 13 93%
Wisconsin 110 105 95% 101 92% 6 5% 107 97% 77 70% 1 1% 75 97%
Wyoming 2 2 100% 2 100% 0 0% 2 100% 0 0% 0 0% 0 0%
City**
Chicago 79 79 100% 71 90% 0 0% 71 90% 58 73% 0 0% 56 97%
District of Columbia 22 22 100% 21 95% 0 0% 21 95% 19 86% 0 0% 19 100%
Houston 92 86 93% 75 82% 2 2% 77 84% 65 71% 1 2% 64 98%
New York City 766 759 99% 739 96% 4 1% 743 97% 705 92% 2 0% 689 98%
Philadelphia 105 103 98% 92 88% 5 5% 97 92% 85 81% 0 0% 83 98%
San Antonio 29 29 100% 27 93% 1 3% 28 97% 23 79% 0 0% 22 96%
Territory
American Samoa 4 4 100% 4 100% 0 0% 4 100% 0 0% 0 0% 0 0%
Guam 7 7 100% 2 29% 2 29% 4 57% 0 0% 0 0% 0 0%
N. Mariana Islands 5 5 100% 5 100% 0 0% 5 100% 3 60% 0 0% 3 100%
Puerto Rico 0 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%
Virgin Islands 2 2 100% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%
Freely Associated Island Nations
Republic of the Marshall Islands 18 18 100% 13 72% 2 11% 15 83% 8 44% 0 0% 8 100%
Micronesia 27 25 93% 4 15% 0 0% 4 15% 4 15% 3 75% 0 0%
Palau 3 2 67% 3 100% 0 0% 3 100% 0 0% 0 0% 0 0%
Download Data (xlsx)

HBIG = hepatitis B immune globulin
HepB = hepatitis B vaccine
HBsAg = hepatitis B surface antigen
anti-HBs = antibody to hepatitis B surface antigen

* These data only include infants followed by the CDC Perinatal Hepatitis B Prevention Program. National and jurisdictional level HepB vaccination coverage rates are available via annual The Morbidity and Mortality Weekly Report (MMWR) publications of National Immunization Survey data and via VaxView.
† Post-vaccination serologic testing (PVST) includes a test for HBsAg, anti-HBs, or both. Results from PVST may be reported as HBsAg positive, HBsAg negative and immune or not immune, or indeterminate.
§ Anti-HBs >10 mIU/mL
¶ Percentage is among infants that completed the vaccine series and received PVST.
** City data are mutually exclusive from state data.

This table summarizes outcome data on infants born to persons with hepatitis B virus infection from the CDC Perinatal Hepatitis B Prevention Program (PHBPP). The 2020 birth cohort includes infants born in 2020 and followed through December 31, 2021.

Among the 7,649 infants whose care was managed by the PHBPP, 95% received recommended prophylaxis at birth, 86% completed the vaccine series (regardless of prophylaxis), and 65% received recommended post-vaccination serologic testing.

Among infants who received post-vaccination testing (4,975), there were 20 (0.4%) cases of perinatal hepatitis B transmission.

Perinatal Hepatitis B Figures and Tables

Table 4.1. Outcomes of infants born in 2021 to persons infected with hepatitis B virus and managed by CDC Perinatal Hepatitis B Prevention Program through the end of 2022 — 64 US Jurisdictions

Figure 4.1. Outcomes of infants born to persons infected with hepatitis B virus and managed by CDC Perinatal Hepatitis B Prevention Program (PHBPP), by birth cohort year — 56 US Jurisdictions, 2009–2021